A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Investigational Drug Acquiring Popularity Online
Retatrutide, which is still in clinical trials, is being promoted by social media influencers for its supposed weight-reducing properties. Followers are encouraged to message these accounts privately for source information, while also receiving promotional offers.
Active Trade on Messaging Platforms
Separately, a robust trade exists on messaging services, where groups with thousands of participants share comparison photos, injection guides and assertions of rapid British shipping. Vendors promote the drug there before redirecting customers to other platforms for purchases.
Learning About Retatrutide
Retatrutide is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could help patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Healthcare Professionals Voice Concerns
However, doctors and pharmacists have warned that the distribution of what remains an unlicensed drug in the UK is worrisome and could lead to users injecting substances of unknown origin.
Some experts stated the demand for the experimental drug could be linked to the increasing price of approved weight loss treatments such as Mounjaro.
Legal Status and Enforcement
Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.
Some influencers attempt to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still violate medicines, advertising, and customer laws, risking fines, prosecution or prison.
Service Response and Material Elimination
Based on the social media company, the service has removed problematic content and prohibited associated keywords and query recommendations. The company said it was committed to keeping the platform secure and allocating resources in enhancing compliance measures.
Digital Trading Operations
Investigations also found groups with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays groups with thousands of users, populated with photos of weight loss, glowing reviews and step-by-step instructions for mixing or administering at residence.
After moments of entering one community, a vendor posted contact information, where the majority of purchases take place. The vendor sent an guidebook and guaranteed shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None inquired about weight, health issues or previous experience.
Item Details and Costs
Inside these communities, messages show black plastic packages with postal service labels, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, prepared at home with sterile water, or ready-to-use injectors usually priced at £160 for 20 milligrams. When asked how long a pen should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.
Platform Oversight and Security Measures
A spokesperson for the messaging service said it actively monitored harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are injecting substances they can’t verify. Even if the research behind retatrutide is valid, these online products may not include what they advertise,” stated a pharmacy expert, the head of pharmacy at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the surge in interest to recent cost increases for authorized weight-loss medications such as Mounjaro. “With prices increasing, patients are using online platforms. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were made in was sterile,” she explained.
Her staff has previously encountered individuals injured by self-injection from unconfirmed sources. “We recognize the frustration, but buying from messaging apps or WhatsApp is gambling with your well-being,” stated Wyllie. “These materials could be impure or improperly measured.”
Producer Position
A representative from Eli Lilly said the substance was in third stage clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can market [it] for human use,” they explained, noting that any item “misleadingly claiming itself as a Lilly experimental product not yet approved … may subject patients to potentially serious health risks”.
